Stephen C. Glover - 24 May 2023 Form 4 Insider Report for ZyVersa Therapeutics, Inc. (ZVSA)

Role
Chief Executive Officer, Director
Signature
/s/ Peter Wolfe as Attorney-in-Fact for Stephen C. Glover pursuant to Power of Attorney
Issuer symbol
ZVSA
Transactions as of
24 May 2023
Net transactions value
$0
Form type
4
Filing time
18 Jul 2024, 21:35:11 UTC
Previous filing
19 May 2023
Next filing
17 Jul 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZVSA Stock Options Award $0 +1,627 $0.000000 1,627 24 May 2023 Common Stock 1,627 $152.46 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option disclosed on this Form 4 was not previously reported due to an administrative oversight.
F2 Share and dollar amounts give effect to the issuer's 1-for-35 reverse stock split effectuated on December 4, 2023, and 1-for-10 reverse stock split effectuated on April 25, 2024.
F3 The option vests annually in three equal installments commencing on May 24, 2024.

Remarks:

Exhibit 24.1 - Power of Attorney